How AI Changed Cardiac Clinical Practice and Outcomes

About this episode

The episode discusses the impact of an FDA-approved cardiac diagnostic AI tool on clinical practice and outcomes.

Health Affairs ' Rob Lott interviews Anna Zink of Tufts University about on her recent paper examining studies of an FDA‑approved cardiac diagnostic AI tool , fractional flow reserve derived from computed tomography. They discuss how the tool shifts testing patterns, raises some costs, reduces invasive procedures, and may improve outcomes—along with what it all means for Medicare reimbursement and the future of AI regulation. Order the March 2026 issue of Health Affairs . Currently, more than 70 percent of our content is freely available - and we'd like to keep it that way. With your support , we can continue to keep our digital publication Forefront and podcast for everyone.

People in this episode

Host: Rob Lott

Guest: Anna Zink

Topics covered

• AI in healthcare
• cardiac diagnostics
• Medicare reimbursement
• clinical outcomes
• health technology

Keywords

• AI
• cardiac
• diagnostic tool
• healthcare
• clinical practice
• outcomes
• Medicare
• regulation

Mentioned in this episode

Organizations: Tufts University, Health Affairs

Products: FDA‑approved cardiac diagnostic AI tool

More episodes of A Health Podyssey

• Private Equity in Primary Care: Costs, Care, and Impact · June 9, 2026 · 21 min
• Inside CVS Caremark: The Role of PBMs in Drug Costs & Access | SPONSORED · June 3, 2026 · 25 min
• Inside CMS: How Medicare Innovation Models Are Working to Lower Costs & Scale Digital Health · June 2, 2026 · 31 min
• Policy Changes Reshaping Family Caregiving · May 27, 2026 · 23 min
• Extreme Heat’s Impact on Healthcare Use and Spending · May 26, 2026 · 19 min
• How the Healthcare Workforce Is Responding to New Aging Policies | Age-Friendly Health Series · May 20, 2026 · 30 min